Nystatin: Difference between revisions
Line 15: | Line 15: | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*Oral candidiasis | |||
**Premature neonates: | |||
***1 mL PO QID of 100,000 U/mL until 48 hrs after symptoms resolve | |||
**Infants: | |||
***2 mL PO QID of 100,000 U/mL until 48 hrs after symptoms resolve | |||
**Children: | |||
***4-6 mL PO QID of 100,000 U/mL until 48 hrs after symptoms resolve | |||
==Special Populations== | ==Special Populations== |
Revision as of 23:20, 14 September 2015
Administration
- Type: Antifungal
- Dosage Forms:
- Routes of Administration:
- PO
- Topical
- Vaginal
- Common Trade Names: Nystop, Nyamyc
Adult Dosing
- Oral Candidiasis:
- 4-6 mL PO QID of 100,000U/mL until 48 hrs after symptoms resolve
- Intestinal candidiasis
- 1-2 tabs (500,000 U) PO TID until 48 hrs after symptoms resolve
Pediatric Dosing
- Oral candidiasis
- Premature neonates:
- 1 mL PO QID of 100,000 U/mL until 48 hrs after symptoms resolve
- Infants:
- 2 mL PO QID of 100,000 U/mL until 48 hrs after symptoms resolve
- Children:
- 4-6 mL PO QID of 100,000 U/mL until 48 hrs after symptoms resolve
- Premature neonates:
Special Populations
- Pregnancy Rating: C
- Lactation risk: Safe
Renal Dosing
- Adult: not defined
- Pediatric: not defined
Hepatic Dosing
- Adult: not defined
- Pediatric: not defined
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Hypersensitivity rxn
Common
- Nausea / Vomiting
- Diarrhea
- Abdominal Pain
Pharmacology
- Half-life: unknown
- Metabolism: CYP450
- Excretion: Feces
Mechanism of Action
- Increases cell membrane permeability by binding to sterols
Comments
See Also
References
- Epocrates 2015